Charles River Labs' Rebound: A Cautionary Tale for Biotech Optimism The biopharma industry's recovery has been a long time coming. Charles River Laboratories International, Inc.
's latest earnings report suggests that even well established players like Charles River Labs are still feeling their way in uncertain terrain.
The company's Q2 2026 numbers show a return to growth after a stagnant period, but beneath the surface lies a complex web of challenges and opportunities. A Sustainable Recovery?